Skip to main content

Nanoviricides, Inc.

NNVC
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001379006

No open-market purchases or sales by Nanoviricides, Inc. insiders were filed in the last 90 days; 47 institutions reported holding it in 13F filings for Q2 2026, worth $3.27M in total; no superinvestor holds it.

Q3 2024 vs. Q2 2024

How the institutions holding Nanoviricides, Inc. changed between Q2 2024 and Q3 2024.

All holders in Q3 2024All holders in Q2 2024

13F holders of NNVC: Q2 2024 compared with Q3 2024
MeasureQ2 2024Of which not filed for Q3 2024Q3 2024Change
Holders34132−1
Shares1.34M158.8K1.34M+155.8K (+13.2%)
Value$2.31M$273.1K$2.01M−$25.9K (−1.3%)

1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Nanoviricides, Inc. at the end of Q3 2024 but not at the end of Q2 2024.

Institutions new to NNVC in Q3 2024
InstitutionSharesValue% of portfolio
BlackRock, Inc.158,752$238.1K0.00%
Dimensional Fund Advisors LP11,915$17.9K0.00%
UBS Group AG2,687$4.03K0.00%
Flaharty Asset Management, LLC400$6000.00%

Sold out (5)

Institutions that held Nanoviricides, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.

Institutions that sold out of NNVC in Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
Verition Fund Management LLC13,003$22.4K
Virtu Financial LLC11,140$19.0K
JPMorgan Chase & Co3,000$5.16K
Main Street Group, LTD200$370
Ashton Thomas Private Wealth, LLC58$100

Not filed for Q3 2024 yet (1)

Institutions that held Nanoviricides, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding NNVC in Q2 2024 that haven't filed for Q3 2024
InstitutionShares, Q2 2024Value, Q2 2024
BlackRock Inc.158,752$273.1K